PBF 677

Drug Profile

PBF 677

Alternative Names: PBF-677

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palobiofarma
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Irritable bowel syndrome

Most Recent Events

  • 27 Sep 2016 Phase-I clinical trials in Irritable bowel syndrome in Spain (PO) prior to September 2016
  • 01 Dec 2015 Phase-I clinical trials in Glaucoma (In volunteers) in Spain (PO) (NCT02639975)
  • 01 Dec 2014 Preclinical trials in Irritable bowel syndrome and Glaucoma in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top